Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPDCs-T Combined with Antivirals in Chronic Hepatitis B
NCT01935635Phase 2Completed
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2015
- Primary completion
- Dec 2019
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HPDCs-T in Chronic Hepatitis B (CHB) (6 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Hepatitis B Virus Markers at 3 years. Started Jan 2015; status: completed.
02
Drugs
HPDCs-T
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01935635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01935635.